Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLC
September 29th 2014
Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.